Management of HBV/HIV-coinfected patients

Seminars in Liver Disease

Volumn 25, Issue SUPPL. 1, 2005, Pages 48-57

  Shire, Norah J ^a   Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Coinfection; HBV; Hepatitis; HIV

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; LIVER ENZYME; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ZIDOVUDINE;

CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG INDICATION; HEMOPHILIA; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION;

ANTIVIRAL AGENTS; COMORBIDITY; DISEASE PROGRESSION; HEPATITIS B; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 24344453349     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915646     Document Type: Review

References (89)

1. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801
2. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-612
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156
4. World Health Organization (WHO) Fact Sheet WHO/204. Hepatitis B. 2000. Available at: www.who.int/mediacentre/ factsheets/fs204/en. Accessed May 11, 2005
5. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169-1177
6. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro-SIDA cohort. AIDS 2005;19:593-601
7. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004;18:2039-2045
8. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
9. MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001;91:965-971
10. Rogers AS, Lindsey JC, Futterman DC, Zimmer B, Abdalian SE, D'Angelo LJ, for the Pediatric AIDS Clinical Trials Group Protocol 220 Team. Serologic examination of hepatitis B infection and immunization in HIV-positive youth and associated risks. AIDS Patient Care STDS 2000;14:651-657
11. Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend 2004;73:69-78
12. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998;178:954-959
13. Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 2000;40:127-131
14. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004;36:869-875
15. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Carballo E, Barrio E. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003;50:2093-2097
16. Centers for Disease Control and Prevention. Diagnoses of HIV/AIDS-32 States, 2000-2003. Morbid Mortal Wkly Rep MMWR 2004;53:1106-1110
17. Kingsley LA, Rinaldo CR Jr, Lyter DW, Valdiserri RO, Belle SH, Ho M. Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA 1990;264:230-234
18. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992;117:837-838
19. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000;95:1316-1322
20. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. Morbid Mortal Wkly Rep MMWR 2004;53: 54-58
21. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32: 294-298
22. Fattovich G, Giustina G, Schalm SW, et al, for the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77-82
23. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135: 759-768
24. Fong TL, Di Bisceglie AM, Biswas R, et al. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. J Med Virol 1994;43:155-158
25. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739
26. Realdi G, Fattovich G, Hadziyannis S, et al, for The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994;21:656-666
27. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-1140
28. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-459
29. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-582
30. Koziel M. The immunopathogenesis of hepatitis B virus infection. In: Schinazi RF, Sommadossi JP, Thomas HC, eds. Therapies for Viral Hepatitis Atlanta, GA: International Medical Press; 1998:53-64
31. Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986;105: 382-383
32. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-582
33. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606
34. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310
35. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035
36. Carton JA, Maradona JA, Asensi V, Rodriguez M, Martinez A. Lamivudine for chronic hepatitis B and HIV co-infection. AIDS 1999;13:1002-1003
37. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M, for the CAESAR Coordinating Committee. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-613
38. Nagai K, Hosaka H, Kubo S, Nakamura N, Shinohara M, Nonaka H. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. J Gastroenterol 1999;34:275-281
39. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-969
40. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306
41. Neau D, Schvoerer E, Robert D, et al. Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient. J Infect 2000;41:192-194
42. Piroth L, Grappin M, Buisson M, Duong M, Portier H, Chavanet P. Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:356-357
43. Saves M, Raffi F, Clevenbergh P, et al, for the APROCO Study Group. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000;44:3451-3455
44. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in southern Italy. J Hepatol 1991;13(suppl 4):S78-S81
45. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology 1991;183:840-844
46. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-850
47. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709
48. Liang TJ, Hasegawa K, Munoz SJ, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994;93:550-555
49. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M, for the Swiss HIV Cohort Study. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Microbiol Infect Dis 1998;17:6-13
50. Vazquez-Vizoso F, Eiroa P, Ledo L, Anibarro L, Hernandez M, Ojea R. HIV infection and isolated detection of anti-HBc. Gastroenterology 1994;106:823-824
51. Sanchez-Quijano A, Jauregui JI, Leal M, et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993;17:288-293
52. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23:14-20
53. Nunez M, Rios P, Perez-Olmeda M, Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002;16:2099-2101
54. Neau D, Winnock M, Jouvencel AC, et al. "Occult" hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005;40:750-753
55. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001;34:194-203
56. Chemin I, Zoulim F, Merle P, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001;34:447-454
57. Mezzelani P, Quaglio G, Venturini L, Lugoboni F. for the Intersert Group of Scientific Collaboration. The significance of the isolated anti-HBc carrier. A study of 1797 drug addicts. Recenti Prog Med 1994;85:419-424
58. Shiota G, Oyama K, Udagawa A, et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol 2000;62:151-158
59. Koyama H, Nishizawa Y, Kinoshita H, Fujimoto T, Morii H. Hepatocellular carcinoma with occult chronic hepatitis-hepatitis B virus as a pathogenetic factor of hepatocellular carcinoma. Osaka City Med J 1988;34:51-66
60. Uchida T, Shimojima S, Gotoh K, Shikata T, Mima S. Pathology of livers infected with "silent" hepatitis B virus mutant. Liver 1994;14:251-256
61. Takeuchi M, Fujimoto J, Niwamoto H, Yamamoto Y, Okamoto E. Frequent detection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis B surface antigen-negative patients. Dig Dis Sci 1997;42:2264-2269
62. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995;21:313-321
63. Thiers V, Nakajima E, Kremsdorf D, et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 1988;2:1273-1276
64. Hoofnagle JH, Seefe LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978;298:1379-1383
65. Scully LJ, Sung H, Pennie R, Gill P. Detection of hepatitis B virus DNA in the serum of Canadian hepatitis B surface antigen negative, anti-HBc positive individuals, using the polymerase chain reaction. J Med Virol 1994;44:293-297
66. Luo KX, Zhou R, He C, Liang ZS, Jiang SB. Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. J Med Virol 1991; 35:55-59
67. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-4071
68. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19:221-240
69. Soriano V, Miro JM, Garcia-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004;11: 2-17
70. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987;7:719-723
71. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-763
72. Zinkernagel RM. Immunity, immunopathology and vaccines against HIV? Vaccine 2002;20:1913-1917
73. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822
74. Katlama C, Ingrand D, Loveday C, et al, for the Lamivudine European HIV Working Group. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-125
75. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-712
76. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306
77. Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002;24:173-181
78. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-245
79. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-723
80. Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002;46:1586-1588
81. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10
82. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-1192
83. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004;39:1062-1064
84. Peters MG, Anderson J, Lynch P, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: results of ACTG A5127. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections: Foundation for Retrovirology and Human Health, February 22-25, 2005; Boston, MA. Available at: www.retroconference.org/Search_ Abstract_2005/AbstractSearch.aspx
85. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582
86. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123: 1831-1838
87. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507
88. Pessoa W, Gazzard B, Huang A, et al. Entecavir in HIV/HBV-co-infected patients: safety and efficacy in a phase II study (ETV-038) (abst 123). Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Available at: www.retroconference.org/2005/CD/ Abstracts/25104.htm
89. Marcellin P, Bernuau J, Martinot-Peignoux M, et al. Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children. Dig Dis Sci 1993;38:2151-2155